Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
205 hedge funds and large institutions have $4.08B invested in Apellis Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 75 increasing their positions, 57 reducing their positions, and 21 closing their positions.
148% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 21
47% more call options, than puts
Call options by funds: $135M | Put options by funds: $91.8M
46% more capital invested
Capital invested by funds: $2.8B → $4.08B (+$1.29B)
32% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 57
17% more funds holding
Funds holding: 175 → 205 (+30)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.65% less ownership
Funds ownership: 80.92% → 80.27% (-0.65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$78.9M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$36.5M |
| 3 |
PA
Perceptive Advisors
New York
|
+$34.1M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$30.9M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$84M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$52.4M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$32.3M |
| 4 |
Goldman Sachs
New York
|
-$22.2M |
| 5 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$19.4M |
APLS Hedge Fund Activity: Q2 2021 in Review
205 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2021, worth a combined $4.08B — up 46% from $2.8B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new APLS positions and 21 closed out — a net gain of 31 holders — while 75 added to existing stakes and 57 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $78.9M. The largest seller was HHLR Advisors, cutting an estimated $84M.
- 205 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2021, up from 175 in Q1 2021.
- Funds reported $4.08B of Apellis Pharmaceuticals stock for Q2 2021, up 46% quarter-over-quarter.
- 52 funds opened new Apellis Pharmaceuticals positions in Q2 2021 and 21 closed out, a net change of +31 holders.
- The largest Apellis Pharmaceuticals buyer in Q2 2021 was T. Rowe Price Associates, an estimated $78.9M added.
- The largest Apellis Pharmaceuticals seller in Q2 2021 was HHLR Advisors, an estimated $84M sold.
Based on aggregated 13F filings for Q2 2021.